Therapeutics/Diagnostics News

PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.

PHILADELPHIA —Higher doses of zegocractin significantly reduced severe organ failure and necrotizing pancreatitis in patients with acute pancreatitis and systemic inflammatory response syndrome, according to late-breaking data.

PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.

PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.

PHILADELPHIA — Patients with a false-positive Shield test result did not appear to be at increased risk for non-colorectal cancer malignancies at 1 year compared with those with a true-negative result, according to a presenter here.

PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.

PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.